Your browser doesn't support javascript.
loading
DNA-Encoded Library Technology-Based Discovery, Lead Optimization, and Prodrug Strategy toward Structurally Unique Indoleamine 2,3-Dioxygenase-1 (IDO1) Inhibitors.
Kazmierski, Wieslaw M; Xia, Bing; Miller, John; De la Rosa, Martha; Favre, David; Dunham, Richard M; Washio, Yoshiaki; Zhu, Zhengrong; Wang, Feng; Mebrahtu, Makda; Deng, Hongfeng; Basilla, Jonathan; Wang, Liping; Evindar, Ghotas; Fan, Lijun; Olszewski, Alison; Prabhu, Ninad; Davie, Christopher; Messer, Jeffrey A; Samano, Vicente.
Affiliation
  • Kazmierski WM; HIV Discovery Performance Unit, GlaxoSmithKline, Research Triangle Park, Durham, North Carolina 27709, United States.
  • Xia B; Encoded Library Technologies/NCE Molecular Discovery, R&D Medicinal Science and Technology, GSK, 200 Cambridge Park Drive, Cambridge, Massachusetts 02140, United States.
  • Miller J; HIV Discovery Performance Unit, GlaxoSmithKline, Research Triangle Park, Durham, North Carolina 27709, United States.
  • De la Rosa M; HIV Discovery Performance Unit, GlaxoSmithKline, Research Triangle Park, Durham, North Carolina 27709, United States.
  • Favre D; HIV Discovery Performance Unit, GlaxoSmithKline, Research Triangle Park, Durham, North Carolina 27709, United States.
  • Dunham RM; HIV Discovery Performance Unit, GlaxoSmithKline, Research Triangle Park, Durham, North Carolina 27709, United States.
  • Washio Y; MST Medicine Design, Medicinal Chemistry, GlaxoSmithKline, Gunnels Wood Rd, Stevenage SG1 2NY, U.K.
  • Zhu Z; Encoded Library Technologies/NCE Molecular Discovery, R&D Medicinal Science and Technology, GSK, 200 Cambridge Park Drive, Cambridge, Massachusetts 02140, United States.
  • Wang F; DMPK/IVIVT, GlaxoSmithKline, 1250 S. Collegeville Rd, Collegeville, Pennsylvania 19426-0989, United States.
  • Mebrahtu M; Screening, Profiling & Mechanistic Biology, RD Platform Technology & Science, GlaxoSmithKline, 1250 S. Collegeville Rd, Collegeville, Pennsylvania 19426-0989, United States.
  • Deng H; Encoded Library Technologies/NCE Molecular Discovery, R&D Medicinal Science and Technology, GSK, 200 Cambridge Park Drive, Cambridge, Massachusetts 02140, United States.
  • Basilla J; Screening, Profiling & Mechanistic Biology, RD Platform Technology & Science, GlaxoSmithKline, 1250 S. Collegeville Rd, Collegeville, Pennsylvania 19426-0989, United States.
  • Wang L; Drug Design and Selection, GlaxoSmithKline, 1250 S. Collegeville Rd, Collegeville, Pennsylvania 19426, United States.
  • Evindar G; Encoded Library Technologies/NCE Molecular Discovery, R&D Medicinal Science and Technology, GSK, 200 Cambridge Park Drive, Cambridge, Massachusetts 02140, United States.
  • Fan L; Encoded Library Technologies/NCE Molecular Discovery, R&D Medicinal Science and Technology, GSK, 200 Cambridge Park Drive, Cambridge, Massachusetts 02140, United States.
  • Olszewski A; Encoded Library Technologies/NCE Molecular Discovery, R&D Medicinal Science and Technology, GSK, 200 Cambridge Park Drive, Cambridge, Massachusetts 02140, United States.
  • Prabhu N; Encoded Library Technologies/NCE Molecular Discovery, R&D Medicinal Science and Technology, GSK, 200 Cambridge Park Drive, Cambridge, Massachusetts 02140, United States.
  • Davie C; Encoded Library Technologies/NCE Molecular Discovery, R&D Medicinal Science and Technology, GSK, 200 Cambridge Park Drive, Cambridge, Massachusetts 02140, United States.
  • Messer JA; Encoded Library Technologies/NCE Molecular Discovery, R&D Medicinal Science and Technology, GSK, 200 Cambridge Park Drive, Cambridge, Massachusetts 02140, United States.
  • Samano V; HIV Discovery Performance Unit, GlaxoSmithKline, Research Triangle Park, Durham, North Carolina 27709, United States.
J Med Chem ; 63(7): 3552-3562, 2020 04 09.
Article in En | MEDLINE | ID: mdl-32073266
ABSTRACT
We report the discovery of a novel indoleamine 2,3-dioxygenase-1 (IDO1) inhibitor class through the affinity selection of a previously unreported indole-based DNA-encoded library (DEL). The DEL exemplar, spiro-chromane 1, had moderate IDO1 potency but high in vivo clearance. Series optimization quickly afforded a potent, low in vivo clearance lead 11. Although amorphous 11 was highly bio-available, crystalline 11 was poorly soluble and suffered disappointingly low bio-availability because of solubility-limited absorption. A prodrug approach was deployed and proved effective in discovering the highly bio-available phosphonooxymethyl 31, which rapidly converted to 11 in vivo. Obtaining crystalline 31 proved problematic, however; thus salt screening was performed in an attempt to circumvent this obstacle and successfully delivered greatly soluble and bio-available crystalline tris-salt 32. IDO1 inhibitor 32 is characterized by a low calculated human dose, best-in-class potential, and an unusual inhibition mode by binding the IDO1 heme-free (apo) form.
Subject(s)

Full text: 1 Database: MEDLINE Main subject: Spiro Compounds / DNA / Prodrugs / Enzyme Inhibitors / Indoleamine-Pyrrole 2,3,-Dioxygenase Limits: Animals Language: En Year: 2020 Type: Article

Full text: 1 Database: MEDLINE Main subject: Spiro Compounds / DNA / Prodrugs / Enzyme Inhibitors / Indoleamine-Pyrrole 2,3,-Dioxygenase Limits: Animals Language: En Year: 2020 Type: Article